In our view, the appointment of Thomas McLain (a recognised leader in diagnostics reimbursement strategy and commercialisation, most recently at Exosome Diagnostics, Inc.) represents a significant step towards achieving national reimbursement of KidneyIntelX™. We continue to expect KidneyIntelX™ to initially follow the CMS (Medicare) ‘crosswalk’ procedure for a test with an existing CPT code (granted by the American Medical Association in July 2019), and believe that national reimbursement could ....
29 Jul 2019
Thomas McLain appointed President and Chief Commercial Officer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Thomas McLain appointed President and Chief Commercial Officer
Renalytix Plc (RENX:LON) | 25.5 -0.3 (-3.8%) | Mkt Cap: 32.2m
- Published:
29 Jul 2019 -
Author:
Jens Lindqvist -
Pages:
3
In our view, the appointment of Thomas McLain (a recognised leader in diagnostics reimbursement strategy and commercialisation, most recently at Exosome Diagnostics, Inc.) represents a significant step towards achieving national reimbursement of KidneyIntelX™. We continue to expect KidneyIntelX™ to initially follow the CMS (Medicare) ‘crosswalk’ procedure for a test with an existing CPT code (granted by the American Medical Association in July 2019), and believe that national reimbursement could ....